Coya Therapeutics IncNASDAQ:COYA
- LAST PRICE7.3500
- TODAY'S CHANGE (%)-0.0100 (-0.1359%)
- Bid / Lots2.9200/ 2
- Ask / Lots9.0000/ 2
- Open / Previous Close7.4900 / 7.3600
- Day Range
- 52 Week Range
- Volume41,988
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | COYA |
|---|---|---|
| 09:32 ET | 516 | 7.49 |
| 09:36 ET | 2000 | 7.22 |
| 09:41 ET | 300 | 7.35 |
| 09:48 ET | 298 | 7.31 |
| 10:12 ET | 500 | 7.4266 |
| 10:48 ET | 100 | 7.37 |
| 10:55 ET | 1000 | 7.3264 |
| 11:02 ET | 561 | 7.3583 |
| 11:22 ET | 250 | 7.36 |
| 11:29 ET | 1580 | 7.55 |
| 11:31 ET | 140 | 7.47 |
| 11:40 ET | 300 | 7.52 |
| 11:49 ET | 1068 | 7.515 |
| 12:05 ET | 100 | 7.39 |
| 12:14 ET | 100 | 7.465 |
| 12:16 ET | 200 | 7.465 |
| 12:45 ET | 16402 | 7.438 |
| 12:48 ET | 200 | 7.44 |
| 01:15 ET | 200 | 7.38 |
| 02:02 ET | 200 | 7.38 |
| 02:08 ET | 200 | 7.38 |
| 02:09 ET | 235 | 7.38 |
| 02:11 ET | 627 | 7.36 |
| 02:13 ET | 144 | 7.4 |
| 02:15 ET | 1200 | 7.405 |
| 02:18 ET | 500 | 7.38 |
| 02:20 ET | 5215 | 7.32 |
| 02:45 ET | 500 | 7.3 |
| 03:16 ET | 100 | 7.34 |
| 03:27 ET | 200 | 7.3 |
| 03:34 ET | 100 | 7.3 |
| 03:36 ET | 100 | 7.25 |
| 03:48 ET | 600 | 7.2101 |
| 03:54 ET | 700 | 7.33 |
| 03:57 ET | 165 | 7.31 |
| 03:59 ET | 200 | 7.35 |
Jul 15, 2024
DJ Coya Shares Rise After Next Step to New Study of ALS Treatment, from 2:10PM ET on Monday Jul 15, 2024 by Dow Jones
2:10PM ET on Monday Jul 15, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Coya Therapeutics Inc | 112.0M | -8.3x | --- |
Armata Pharmaceuticals Inc | 108.5M | -1.3x | --- |
CervoMed Inc | 118.6M | 7.1x | --- |
Vaxart Inc | 120.1M | -1.3x | --- |
Adlai Nortye Ltd | 127.2M | -0.5x | --- |
Assembly Biosciences Inc | 90.8M | -1.3x | --- |
Company Information
Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in developing treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The Company's 300 Series product candidates include COYA 301 and COYA 302.
Contact Information
- Headquarters
- 5850 San Felipe St., Suite 500HOUSTON, TX, United States 77057
- Phone
- 650-739-3939
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer
- Howard Berman
- President, Chief Medical Officer
- Fred Grossman
- Chief Financial Officer, Chief Operating Officer
- David Snyder
- Director
- Wilbur Ross
- Director
- Dieter Weinand
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $112.0M |
|---|---|
Revenue (TTM) | $6.1M |
Shares Outstanding | 15.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.89 |
Book Value | $2.47 |
P/E Ratio | -8.3x |
Price/Sales (TTM) | 18.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -171.09% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
